Related Experiment Videos
The USA experience with the clonidine transdermal therapeutic system
1Department of Medicine, Georgetown University Medical Center, Washington, DC.
Insights
Transdermal clonidine effectively manages hypertension throughout the day and is well-tolerated across diverse patient groups. This formulation offers improved side-effect profiles and patient adherence compared to oral clonidine.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Cardiovascular diseases are a leading cause of death in the U.S.
- Hypertension is a major cardiovascular risk factor requiring effective management strategies.
- Transdermal clonidine has accumulated extensive clinical experience since its U.S. market introduction.
Purpose of the Study:
- To evaluate the efficacy and tolerability of transdermal clonidine for hypertension management.
- To compare the side-effect profile and patient adherence of transdermal versus oral clonidine.
- To assess the utility of transdermal clonidine in various patient populations and clinical scenarios.
Main Methods:
- Review of pre- and post-marketing data for transdermal clonidine.
- Analysis of clinical experience in mild-moderate hypertension and resistant cases.
- Comparison of transdermal clonidine with oral clonidine regarding efficacy and side effects.
Main Results:
- Transdermal clonidine is effective as monotherapy and in combination therapy for hypertension.
- It provides 24-hour blood pressure control and is well-tolerated in diverse populations including adolescents, elderly, Black patients, diabetics, and those with renal insufficiency.
- Transdermal clonidine demonstrates a reduced incidence of symptomatic side effects (e.g., dry mouth, drowsiness) compared to oral formulations, with high patient adherence and preference.
Conclusions:
- Transdermal clonidine is a valuable therapeutic option for long-term hypertension management.
- It offers improved tolerability and patient convenience over oral clonidine.
- Its efficacy and safety profile support its use in a broad range of hypertensive patients.
Abstract:
Cardiovascular diseases are the leading causes of death in the United States, with hypertension being amongst the most prevalent of the cardiovascular risk factors. Improvement of hypertension management has, in consequence, received much attention. Extensive pre- and post-marketing experience with the transdermal formulation of clonidine marketed in the USA in the mid-1980s has now been accumulated. Transdermal clonidine is effective as monotherapy in mild-moderate hypertension, and in combination with diuretics, calcium antagonists and ACE inhibitors in more resistant cases. It controls blood pressure throughout the 24-h circadian cycle. It is effective and generally well-tolerated in adolescents, the elderly, blacks, diabetics, and subjects with chronic renal insufficiency. It has been used perioperatively and for suppression of adrenergic symptoms in subjects withdrawing from addicting substances. In comparison with oral clonidine, transdermal clonidine reduces the incidence and severity of such symptomatic side-effects as dry mouth, drowsiness, and sexual dysfunction. Minor skin reactions occur at the site of application of the transdermal patch with moderate frequency. Adherence to transdermal clonidine therapy is high, and patients commonly prefer it to oral therapy. Transdermal administration of clonidine is a useful therapeutic advance in the long-term management of hypertension.